Intercept Pharmaceuticals (NASDAQ:ICPT) : Wednesdays money flow points at investors jumping to buy the stock on the weakness of price. $17.78 million worth of transactions were on upticks, whereas, the downticks accounted for $17.01 million worth of transactions. The net money flow was a positive $0.77 million and the uptick to downtick ratio was 1.05. The net money flow into the stock was $0.01 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $0.01 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Intercept Pharmaceuticals (NASDAQ:ICPT) was trading at $149.34, down $0.03 during day. The stock slid -0.02% over the previous days close. For the week, the stock recorded 4.49% over the previous weeks close.
In an insider trading activity, The Securities and Exchange Commission has divulged that Bright Lisa, officer (See Remarks) of Intercept Pharmaceuticals Inc, had unloaded 251 shares at an average price of $137.5 in a transaction dated on May 25, 2016. The total value of the transaction was worth $34,513. Currently the company Insiders own 9.2% of Intercept Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.25% . Institutional Investors own 76.47% of Intercept Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of 1.81%.
The company shares have dropped -37.04% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $285.00 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $144.60 and the 200 Day Moving Average price is recorded at $134.50. Intercept Pharmaceuticals (NASDAQ:ICPT): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $150.94 and $146.20 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $151.95. The buying momentum continued till the end and the stock did not give up its gains. It closed at $149.87, notching a gain of 0.33% for the day. The total traded volume was 577,761 . The stock had closed at $149.37 on the previous day.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials, including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.